logo-loader
viewTissue Regenix Group PLC

Tissue Regenix to expand sales force after latest US DermaPure approvals

Antony Odell, the chief executive of Tissue Regenix (LON:TRX) says he will expand the firm’s sales division after its Derma Pure skin graft gained approval for coverage in over half of the American states.

Noridian Healthcare Solutions and Palmetto GBA’s green light means DermaPure is now available to 20.7mln patients on Medicare across 30 states.


Medicare, the US government’s health care insurance programme for the over 65s, is key to the company’s strategy for Dermapure. Approval by a Medicare administrator mean doctors and hospitals receive reimbursement for using the product.

Quick facts: Tissue Regenix Group PLC

Price: 1.1749 GBX

AIM:TRX
Market: AIM
Market Cap: £13.77 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016

RNS

Directorate Change

1 hour, 52 minutes ago

Holding(s) in Company

4 days, 1 hour ago

Holding(s) in Company

5 days, 2 hours ago

Holding(s) in Company

5 days, 2 hours ago

2 min read